This section focuses on how interactions between antioxidant enzymes and other molecules can either prevent the production of ROS or enhance their efficient deactivation
It is alleged that the manufacturers, Novo Nordisk and Eli Lilly knew or should have known about the risks associated with these drugs and failed to warn consumers
The FDA has issued multiple warnings about these products because of: Unknown quality Incorrect or impure ingredient (salt forms) Lack of sterility Incorrect dosing Risk of contamination Therefore, only use FDA-approved peptides or get your medication from a certified healthcare provider or a 503a compounding pharmacy
But not everybody has access to them
Possible effect modification by age, sex, diabetes status, glycemic control, obesity, CVD, and other comorbidities, as well as compounds, administration methods, and dosages of GLP-1 RAs should be evaluated